Tendersinfo Gulf

Filter Search

Healthcare and Medical

Location Summary Deadline
Germany The Dak-gesundheit Is Seeking To Establish A Non-exclusive Discount Agreement For The Active Ingredient Aflibercept (excluding 114.3 Mg/ml) For The Period From December 1, 2025, To November 30, 2027. The Agreement Allows All Pharmaceutical Companies To En 2026-04-16
Germany The Dak-gesundheit Is Entering Into A Non-exclusive Discount Agreement For The Active Ingredient Tocilizumab (only Pre-filled Syringe And Pre-filled Pen) For The Period From December 1, 2025, To November 30, 2027. This Procedure Is Expected To Fall Outsid 2026-04-16
Germany Conclusion Of Non-exclusive Discount Agreements In Accordance With Section 130a Paragraph. 8 Sgb V On The Active Ingredients Mentioned With The Possibility Of Contracting Within The Framework Of The So-called Openhouse Procedure. 2026-04-16
Germany Open House Drug Discount Agreements For The Active Ingredient Rotigotine, Atc N04bc09 2026-04-16
Germany Open House Drug Discount Agreements For The Active Ingredient Diltiazem, Atc C08db01 2026-04-16
Germany Conclusion Of Non-exclusive Discount Agreements In Accordance With Section 130a Paragraph. 8 Sgb V On The Active Ingredients Mentioned With The Possibility Of Contracting Within The Framework Of The So-called Openhouse Procedure. 2026-04-16
Germany Conclusion Of Non-exclusive Discount Agreements In Accordance With Section 130a Paragraph 8 Sgb V For The Active Ingredients Mentioned With The Possibility Of Conclusion Within The Framework Of The So-called Open House Procedure. 2026-04-16
Germany Open House Drug Discount Agreements For The Active Ingredient Sarilumab, Atc L04ac14 2026-04-18
Germany Conclusion Not Excluding Drug Discount Agreement. According To Section 130a Paragraph 8 Sgb V Through An Open House Model For The Active Ingredient Teriparatide (atc Code According To Who: H05aa02) 2026-04-18
Germany Open House Biologics Discount Agreements 2025-31 - Denosumab 2026-04-18
Whats app